GDTC – cytomed therapeutics limited - ordinary shares (US:NASDAQ)
Stock Stats
News
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
CytoMed Therapeutics Limited (NASDAQ: GDTC) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $5.00 price target on the stock.
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
Form 6-K CytoMed Therapeutics For: Nov 20
Form 144 CytoMed Therapeutics Filed by: mDR Ltd
Form 6-K CytoMed Therapeutics For: Oct 07
Form 6-K CytoMed Therapeutics For: Oct 03
Form 6-K CytoMed Therapeutics For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.